title: Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells.
abstract: Glioblastoma Multiforme (GBM) is a malignant primary brain tumor associated with poor survival rate. PI3K/Akt pathway is highly upregulated in gliomas due to deletion or mutation of PTEN and its activation is associated with tumor grade. mTOR is downstream from PI3K/Akt pathway and it initiates translation through its action on S6K and 4E-BP1. mTOR is an important therapeutic target in many cancers, including glioblastomas. Rapamycin and its analogues are known to inhibit mTOR pathway; however, they also show simultaneous upregulation of Akt and eIF4E survival pathways on inhibition of mTOR, rendering cells more resistant to rapamycin treatment. In this study we investigated the effect of combination treatment of rapamycin with isoflavones such as genistein and biochanin A on mTOR pathway and activation of Akt and eIF4E in human glioblastoma (U87) cells. Our results show that combination treatment of rapamycin with isoflavones, especially biochanin A at 50 muM, decreased the phosphorylation of Akt and eIF4E proteins and rendered U87 cells more sensitive to rapamycin treatment when compared to cells treated with rapamycin alone. These results suggest the importance of combining chemopreventive with chemotherapeutic agents in order to increase the efficacy of chemotherapeutic drugs.
authors.affiliation: Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy and Idaho Biomedical Research Institute, Idaho State University, Pocatello, ID 83209-8334, USA.
authors.forename: Shilpa
authors.initials: S
authors.lastname: Puli
authors.forename: Aditi
authors.initials: A
authors.lastname: Jain
authors.forename: James C K
authors.initials: JC
authors.lastname: Lai
authors.forename: Alok
authors.initials: A
authors.lastname: Bhushan
mesh_terms: D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004357:Drug Synergism; D039561:Eukaryotic Initiation Factor-4E / Q000378:metabolism; D019833:Genistein / Q000494:pharmacology; D005909:Glioblastoma; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000502:physiology*; D007529:Isoflavones / Q000494:pharmacology*; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases / Q000502:physiology*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction; D020123:Sirolimus / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases
chemical_list: D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D039561:Eukaryotic Initiation Factor-4E; D047908:Intracellular Signaling Peptides and Proteins; D007529:Isoflavones; D019833:Genistein; C546842:MTOR protein, human; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; C004541:biochanin A; D020123:Sirolimus